Evotec (EVO) said Wednesday the company, alongside Yonsei University and biotech firm Zymedi, will receive a $4.5 million grant from the Korea Institute of Advanced Technology to fund the development of therapies to treat lung diseases.
The company said the project will focus on development of new anti-inflammatory and anti-fibrotic antibodies to treat diseases with unmet medical needs, including idiopathic pulmonary fibrosis and non-type 2 asthma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.